Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Markets
Screener
News
About

Home

VKTX

V

Viking Therapeutics, Inc. (VKTX)

NCM – Real Time Price. Currency in USD

32.52

-1.73 (-5.05%)

At close: Mar 27, 2026, 4:00 PM EDT

32.49

-0.03 (-0.09%)

After-hours: Mar 27, 2026, 7:57 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

VKTX Finishes Enrollment in Second Late-Stage Study on Obesity Drug

VKTX Finishes Enrollment in Second Late-Stage Study on Obesity Drug

Viking Therapeutics climbs after it completes enrollment in the second phase III obesity study for VK2735 and advances its bid in a fast-growing, competitive weight-loss market.

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735

78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the completion of patient enrollment in its Phase 3 VANQUISH-2 clinical trial of subcutaneous VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2735 is being developed in both oral and subcutaneous formulations for the potential treatment of metabolic disorders such as obesity.

Why Viking Therapeutics, Inc. (VKTX) Dipped More Than Broader Market Today

Why Viking Therapeutics, Inc. (VKTX) Dipped More Than Broader Market Today

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $32.17, denoting a -1.17% move from the preceding trading day.

Why Viking Therapeutics Stock Could Take Off Later This Year

Why Viking Therapeutics Stock Could Take Off Later This Year

Viking's GLP-1 drug, VK2735, is currently in the midst of multiple clinical trials. The company is evaluating whether it can be taken monthly for maintenance dosing.

Got $1,500? Is It Better to Buy Bitcoin, or Viking Therapeutics?

Got $1,500? Is It Better to Buy Bitcoin, or Viking Therapeutics?

Viking Therapeutics has a very promising candidate in its pipeline. Under certain conditions, that could make it grow a lot.

Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics

Better Weight Loss Drug Stock Buy: Eli Lilly vs Viking Therapeutics

Eli Lilly is the leader in the U.S. weight loss drug market, with a 60% share. Viking aims to enter this market -- and so far, its clinical trial results have been strong.

Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider

Viking Therapeutics, Inc. (VKTX) Exceeds Market Returns: Some Facts to Consider

Viking Therapeutics, Inc. (VKTX) reached $36.01 at the closing of the latest trading day, reflecting a +1.07% change compared to its last close.

Videos

No Data

There is no data to display

Press releases

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735

78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the completion of patient enrollment in its Phase 3 VANQUISH-2 clinical trial of subcutaneous VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2735 is being developed in both oral and subcutaneous formulations for the potential treatment of metabolic disorders such as obesity.

Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

Conference call scheduled for 4:30 p.m. ET today Oral VK2735 to Advance into Phase 3 for Obesity in 3Q26 Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Ongoing; VANQUISH-1 Enrollment Complete, VANQUISH-2 Nearing Full Enrollment VK2735 Maintenance Dosing Study Fully Enrolled; Data Expected 3Q26 Novel Amylin Agonist IND Filing Planned This Quarter Strong Quarter-End Cash Position of $706 Million SAN DIEGO, Feb. 11, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the fourth quarter and year ended December 31, 2025, and provided an update on its clinical pipeline and other corporate developments.

Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity

Viking Therapeutics Announces Publication of Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in the Journal Obesity

Publication Highlights Impressive Weight Loss of Up to 14.7% from Baseline After 13 Weeks of Treatment; No Plateau Observed VK2735 Currently Being Evaluated in VANQUISH Phase 3 Registrational Program in Obesity SAN DIEGO, Jan. 12, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the publication of the results of the company's Phase 2 VENTURE clinical trial of VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2375 is being developed in both oral and subcutaneous formulations for the potential treatment of various metabolic disorders such as obesity.

Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity

Viking Therapeutics Announces Completion of Enrollment in Maintenance Dosing Clinical Trial of VK2735 in Obesity

Study is Evaluating Monthly Subcutaneous, Weekly Oral, and Daily Oral Regimens Designed to Explore Maintenance Dosing Regimens Following Initial Weight Loss with VK2735 SAN DIEGO, Jan. 8, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the completion of patient enrollment in its exploratory maintenance dosing study of VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. VK2375 is being developed in both oral and subcutaneous formulations for the potential treatment of various metabolic disorders such as obesity.